Kuen Chan

550 total citations
20 papers, 453 citations indexed

About

Kuen Chan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Kuen Chan has authored 20 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kuen Chan's work include Prostate Cancer Treatment and Research (12 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Kuen Chan is often cited by papers focused on Prostate Cancer Treatment and Research (12 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Kuen Chan collaborates with scholars based in China, Hong Kong and United States. Kuen Chan's co-authors include Ricky Ngok‐Shun Wong, Daisy Y.L. Wong, Chitat Chan, Darren M.C. Poon, Michael C.H. Lee, Rick Chappell, Anne W.M. Lee, T.K. Yau, Wai-Man Sze and Albert W.M. Hung and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Kuen Chan

17 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kuen Chan China	8	192	124	98	97	92	20	453
Yizhuo Li China	15	80 0.4×	347 2.8×	70 0.7×	13 0.1×	32 0.3×	34	650
Xinan Wang China	15	387 2.0×	267 2.2×	21 0.2×	13 0.1×	46 0.5×	46	709
M F Melhem United States	13	118 0.6×	332 2.7×	40 0.4×	6 0.1×	44 0.5×	22	731
Yuchao Ma China	10	82 0.4×	126 1.0×	19 0.2×	7 0.1×	16 0.2×	32	341
Yasuhiro Kidera Japan	9	62 0.3×	173 1.4×	9 0.1×	45 0.5×	6 0.1×	12	448
Damodar B. Balar India	14	54 0.3×	266 2.1×	29 0.3×	8 0.1×	16 0.2×	41	548
Mitsuhiro Miyazaki Japan	13	137 0.7×	156 1.3×	13 0.1×	11 0.1×	14 0.2×	22	397
Tso‐Fu Wang Taiwan	13	67 0.3×	135 1.1×	3 0.0×	21 0.2×	31 0.3×	47	430
B. Giroux France	13	139 0.7×	154 1.2×	21 0.2×	9 0.1×	11 0.1×	23	438

Countries citing papers authored by Kuen Chan

Since Specialization

Citations

This map shows the geographic impact of Kuen Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kuen Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kuen Chan more than expected).

Fields of papers citing papers by Kuen Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kuen Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kuen Chan. The network helps show where Kuen Chan may publish in the future.

Co-authorship network of co-authors of Kuen Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Kuen Chan. A scholar is included among the top collaborators of Kuen Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kuen Chan. Kuen Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chan, Kuen, et al.. (2024). Volumetric Modulated Arc Therapy for High-Risk and Very High-Risk Locoregional Prostate Cancer in the Modern Era: Real-World Experience from an Asian Cohort. Cancers. 16(17). 2964–2964.

Poon, Darren M.C., GuangMing Tan, Kuen Chan, et al.. (2024). Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology. Frontiers in Oncology. 14. 1345322–1345322. 1 indexed citations

Poon, Darren M.C., et al.. (2023). Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune checkpoint inhibitors. Drugs in Context. 12. 1–9. 3 indexed citations

Chan, Kuen, et al.. (2023). A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer. Clinical Genitourinary Cancer. 22(1). e75–e85.e1. 5 indexed citations

Poon, Darren M.C., Kuen Chan, Tim Chan, et al.. (2022). Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer. Cancers. 14(2). 407–407. 6 indexed citations

Poon, Darren M.C., et al.. (2022). Recommendations for the management of advanced and metastatic renal cell carcinoma: joint consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology. Hong Kong Medical Journal. 28(6). 475–481. 1 indexed citations

Poon, Darren M.C., et al.. (2021). Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients. Asia-Pacific Journal of Clinical Oncology. 17(S3). 39–47. 8 indexed citations

Chan, Kuen, et al.. (2021). Consensus statements on the management of metastatic renal cell carcinoma from the Hong Kong Urological Association and the Hong Kong Society of Uro‐Oncology 2019. Asia-Pacific Journal of Clinical Oncology. 17(S3). 27–38. 2 indexed citations

Poon, Darren M.C., Kuen Chan, Tim Chan, et al.. (2020). 219MO Real-world utilization pattern of bone-targeted agents for metastatic prostate cancer: Web-based questionnaire study by Hong Kong Society of Uro-Oncology (HKSUO). Annals of Oncology. 31. S1326–S1326.

10.

Poon, Darren M.C., et al.. (2020). Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factors (GCSF) in Chinese metastatic hormonal-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 72–72. 1 indexed citations

11.

Poon, Darren M.C., et al.. (2018). Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong. Clinical Genitourinary Cancer. 16(5). 402–412.e1. 16 indexed citations

12.

Teoh, Jeremy Yuen‐Chun, Darren M.C. Poon, Tim Chan, et al.. (2018). A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer. Clinical Genitourinary Cancer. 17(1). e203–e208. 5 indexed citations

13.

Poon, Darren M.C., et al.. (2018). The survival outcome, prostate-specific antigen (PSA) response and risk of fatigue of enzalutamide as first- and later-line treatment options in patients with metastatic castration-resistant prostate cancer (mCRPC): The real-world experience.. Journal of Clinical Oncology. 36(6_suppl). 330–330. 1 indexed citations

14.

Poon, Darren M.C., et al.. (2018). Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone‐naïve prostate cancer: The first real‐life experience in Asia. Asia-Pacific Journal of Clinical Oncology. 14(4). 347–352. 16 indexed citations

15.

Poon, Darren M.C., et al.. (2017). Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study. Prostate International. 6(1). 24–30. 10 indexed citations

16.

Poon, Darren M.C., et al.. (2016). Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience. BMC Urology. 16(1). 12–12. 44 indexed citations

17.

Poon, Darren M.C., et al.. (2015). Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer. Prostate International. 3(2). 51–55. 21 indexed citations

18.

Sze, Wai-Man, Anne W.M. Lee, T.K. Yau, et al.. (2004). Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. International Journal of Radiation Oncology*Biology*Physics. 59(1). 21–27. 170 indexed citations

19.

Chan, Kuen, et al.. (2004). Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Life Sciences. 75(26). 3157–3171. 142 indexed citations

20.

Sze, W.M., Macy Tong, Chin Teck Ng, et al.. (2004). Preliminary experience on treating advanced nasopharyngeal carcinoma (NPC) affecting/abutting neurological structures with induction chemotherapy followed by concurrent chemo-radiation with accelerated fractionation. Journal of Clinical Oncology. 22(14_suppl). 5525–5525. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact